Mutation in the Kinase Domain Alters the VEGFR2 Membrane Dynamics

被引:0
|
作者
Corsini, Michela [1 ,2 ]
Ravelli, Cosetta [1 ,3 ]
Grillo, Elisabetta [1 ,3 ]
Domenichini, Mattia [1 ]
Mitola, Stefania [1 ,2 ,3 ]
机构
[1] Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy
[2] CN3 Sviluppo Terapia Genica & Farm Tecnol RNA, I-25123 Brescia, Italy
[3] CIB Consorzio Interuniv Biotecnol, I-25123 Brescia, Italy
关键词
TK receptors; FLIM/FRET; FRAP; molecular interaction; VEGFR2; RECEPTOR; PROTEIN; GROWTH; CYAN; FRET;
D O I
10.3390/cells13161346
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Recently, the substitution R1051Q in VEGFR2 has been described as a cancer-associated "gain of function" mutation. VEGFR2R1051Q phosphorylation is ligand-independent and enhances the activation of intracellular pathways and cell growth both in vitro and in vivo. In cancer, this mutation is found in heterozygosity, suggesting that an interaction between VEGFR2R1051Q and VEGFR2WT may occur and could explain, at least in part, how VEGFR2R1051Q acts to promote VEGFR2 signaling. Despite this, the biochemical/biophysical mechanism of the activation of VEGFR2R1051Q remains poorly understood. On these bases, the aim of our study is to address how VEGFR2R1051Q influences the biophysical behavior (dimerization and membrane dynamics) of the co-expressed VEGFR2WT. Methods: We employed quantitative FLIM/FRET and FRAP imaging techniques using CHO cells co-transfected with the two forms of VEGFR2 to mimic heterozygosity. Results: Membrane protein biotinylation reveals that VEGFR2WT is more exposed on the cell membrane with respect to VEGFR2R1051Q. The imaging analyses show the ability of VEGFR2WT to form heterodimers with VEGFR2R1051Q and this interaction alters its membrane dynamics. Indeed, when the co-expression of VEGFR2WT/VEGFR2R1051Q occurs, VEGFR2WT shows reduced lateral motility and a minor pool of mobile fraction. Conclusions: This study demonstrates that active VEGFR2R1051Q can affect the membrane behavior of the VEGFR2WT.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Substrate-Specific Conformational Regulation of the Receptor Tyrosine Kinase VEGFR2 Catalytic Domain
    Solowiej, James
    Chen, Jeffrey H.
    Zou, Helen Y.
    Grant, Stephan K.
    Murray, Brion W.
    ACS CHEMICAL BIOLOGY, 2013, 8 (05) : 978 - 986
  • [2] The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling
    Jopling, Helen M.
    Howell, Gareth J.
    Gamper, Nikita
    Ponnambalam, Sreenivasan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 410 (02) : 170 - 176
  • [3] Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
    Dev, IK
    Dornsife, RE
    Hopper, TM
    Onori, JA
    Miller, CG
    Harrington, LE
    Dold, KM
    Mullin, RJ
    Johnson, JH
    Crosby, RM
    Truesdale, AT
    Epperly, AH
    Hinkle, KW
    Cheung, M
    Stafford, JA
    Luttrell, DK
    Kumar, R
    BRITISH JOURNAL OF CANCER, 2004, 91 (07) : 1391 - 1398
  • [4] Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
    I K Dev
    R E Dornsife
    T M Hopper
    J A Onori
    C G Miller
    L E Harrington
    K M Dold
    R J Mullin
    J H Johnson
    R M Crosby
    A T Truesdale
    A H Epperly
    K W Hinkle
    M Cheung
    J A Stafford
    D K Luttrell
    R Kumar
    British Journal of Cancer, 2004, 91 : 1391 - 1398
  • [5] Biochemical and Conformational Characterization of Recombinant VEGFR2 Domain 7
    Rossella Di Stasi
    Donatella Diana
    Lucia De Rosa
    Roberto Fattorusso
    Luca D. D’Andrea
    Molecular Biotechnology, 2019, 61 : 860 - 872
  • [6] Biochemical and Conformational Characterization of Recombinant VEGFR2 Domain 7
    Di Stasi, Rossella
    Diana, Donatella
    De Rosa, Lucia
    Fattorusso, Roberto
    D'Andrea, Luca D.
    MOLECULAR BIOTECHNOLOGY, 2019, 61 (11) : 860 - 872
  • [7] Inhibition of VEGFR2 dimerisation, a novel mechanism of inhibiting VEGFR2 signaling
    Kendrew, Jane
    Kang, Jaspal
    Eberlein, Cath
    Foltz, Ian
    Hedberg, Brad
    Zhou, Joe
    McDaid, Karen
    Weir, Hazel
    Barry, Simon
    CANCER RESEARCH, 2009, 69
  • [8] Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
    Yuan, Xiao-Han
    Yang, Jie
    Wang, Xin-Yue
    Zhang, Xiao-Ling
    Qin, Ting-Ting
    Li, Kai
    ONCOLOGY LETTERS, 2018, 16 (02) : 2105 - 2112
  • [9] Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression
    Liu, Tingting
    Li, Yonghao
    Su, Hong
    Zhang, Haifeng
    Jones, Dennis
    Zhou, Huanjiao Jenny
    Ji, Weidong
    Min, Wang
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (01) : 126 - 138
  • [10] Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: Comparison of binding to non-phosphorylated and phosphorylated VEGFR2
    Iwata, Hidehisa
    Imamura, Shinichi
    Hori, Akira
    Hixon, Mark S.
    Kimura, Hiroyuki
    Miki, Hiroshi
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (18) : 5342 - 5351